Histone acetyltransferase modulators and uses thereof

Patent metadata

Field	Value
Publication number	US-9969677-B2
Application number	US-201113996483-A
Country	US
Kind code	B2
Filing date	Dec 22, 2011
Priority date	Dec 22, 2010
Publication date	May 15, 2018
Grant date	May 15, 2018

Abstract

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.

First claim

What is claimed is:

1. A compound of any one of the formulae below:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition, comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

4. A pharmaceutical composition, comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition, comprising the compound of claim 5 , and at least one pharmaceutically acceptable carrier.

13. A pharmaceutical composition, comprising the compound of claim 6 , and at least one pharmaceutically acceptable carrier.

14. A pharmaceutical composition, comprising the compound of claim 7 , and at least one pharmaceutically acceptable carrier.

15. A pharmaceutical composition, comprising the compound of claim 8 , and at least one pharmaceutically acceptable carrier.

16. A pharmaceutical composition, comprising the compound of claim 9 , and at least one pharmaceutically acceptable carrier.

17. A pharmaceutical composition, comprising the compound of claim 10 , and at least one pharmaceutically acceptable carrier.

18. A pharmaceutical composition, comprising the compound of claim 11 , and at least one pharmaceutically acceptable carrier.

Assignees

• Francis Yitshak
• Fa Mauro
• Arancio Ottavio
• Fiorito Jole
• Deng Shixian
• Landry Donald W
• Luzac Michal
• Feng Yan
• Univ Columbia

Inventors

• Francis Yitshak
• Fa Mauro
• Arancio Ottavio
• Fiorito Jole
• Deng Shixian
• Landry Donald W
• Luzac Michal
• Feng Yan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P39/02

  Antidotes · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P5/38

  of the suprarenal hormones · CPC title

• A61P35/00

  Antineoplastic agents · CPC title